The patient journey and burden of disease in Demodex blepharitis in the United States.

IF 2.9 4区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Journal of Medical Economics Pub Date : 2025-12-01 Epub Date: 2025-05-21 DOI:10.1080/13696998.2025.2500224
Laura M Periman, Walter O Whitley, Sathi Maiti, James Mun, Anh N Ho, Bhagyashree Oak, Amod Athavale, Elizabeth Yeu
{"title":"The patient journey and burden of disease in <i>Demodex</i> blepharitis in the United States.","authors":"Laura M Periman, Walter O Whitley, Sathi Maiti, James Mun, Anh N Ho, Bhagyashree Oak, Amod Athavale, Elizabeth Yeu","doi":"10.1080/13696998.2025.2500224","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong><i>Demodex</i> blepharitis (DB) is a chronic eyelid disease caused by an infestation of <i>Demodex</i> mites. The objective of this chart audit study was to characterize the patient journey and burden of illness associated with DB from an eye-care provider's perspective.</p><p><strong>Methods: </strong>Retrospective medical data for patients with a confirmed diagnosis of DB were anonymously collected <i>via</i> ophthalmologists and optometrists in the US (collectively eye-care providers [ECPs]), in June-July 2022. Each eligible ECP completed a questionnaire and provided chart abstractions of 1-5 medical charts of patients with DB in an electronic case report form.</p><p><strong>Results: </strong>All ECPs (<i>N</i> = 61) were ophthalmologists or optometrists who worked primarily in office-based private practices (97%). Data from 192 medical charts of patients with an ECP-confirmed diagnosis of DB were abstracted and their demographics included 54% males and 71% Caucasians. The mean time (±SD) since diagnosis was 11 (±9.0) years. Over 40% of patients were not examined for DB at initial presentation, and the average time from initial presentation to a definitive diagnosis for DB was 6.5 months. After DB diagnosis and across the period of observation until the time of the study, patients had a mean (±SD) of 3.2 (±2.8) follow-up visits due to DB and continued to use multiple off-label prescription and over-the-counter therapies for symptom management.</p><p><strong>Limitation: </strong>Medical records may be incomplete or inconsistently reported and subject to recall bias.</p><p><strong>Conclusions: </strong>The patient journey is lengthy with multiple challenges, including delay in DB diagnosis and recurring DB symptoms, underlining an urgent need for action to improve diagnosis and treatment of DB.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"734-742"},"PeriodicalIF":2.9000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13696998.2025.2500224","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: Demodex blepharitis (DB) is a chronic eyelid disease caused by an infestation of Demodex mites. The objective of this chart audit study was to characterize the patient journey and burden of illness associated with DB from an eye-care provider's perspective.

Methods: Retrospective medical data for patients with a confirmed diagnosis of DB were anonymously collected via ophthalmologists and optometrists in the US (collectively eye-care providers [ECPs]), in June-July 2022. Each eligible ECP completed a questionnaire and provided chart abstractions of 1-5 medical charts of patients with DB in an electronic case report form.

Results: All ECPs (N = 61) were ophthalmologists or optometrists who worked primarily in office-based private practices (97%). Data from 192 medical charts of patients with an ECP-confirmed diagnosis of DB were abstracted and their demographics included 54% males and 71% Caucasians. The mean time (±SD) since diagnosis was 11 (±9.0) years. Over 40% of patients were not examined for DB at initial presentation, and the average time from initial presentation to a definitive diagnosis for DB was 6.5 months. After DB diagnosis and across the period of observation until the time of the study, patients had a mean (±SD) of 3.2 (±2.8) follow-up visits due to DB and continued to use multiple off-label prescription and over-the-counter therapies for symptom management.

Limitation: Medical records may be incomplete or inconsistently reported and subject to recall bias.

Conclusions: The patient journey is lengthy with multiple challenges, including delay in DB diagnosis and recurring DB symptoms, underlining an urgent need for action to improve diagnosis and treatment of DB.

美国蠕形螨性眼睑炎的患者旅程和疾病负担。
目的:蠕形螨眼炎(DB)是一种由蠕形螨感染引起的慢性眼睑疾病。本图表审核研究的目的是从眼保健提供者的角度描述与DB相关的患者旅程和疾病负担。方法:在2022年6月至7月期间,通过美国眼科医生和验光师(统称为眼保健提供者[ECPs])匿名收集确诊为DB的患者的回顾性医疗数据。每位合格的ECP完成一份调查问卷,并以电子病例报告形式提供1-5例DB患者的病历摘要。结果:所有ecp (N = 61)均为主要在办公室私人诊所工作的眼科医生或验光师(97%)。从192例经ecp确诊的DB患者病历中提取数据,其中男性占54%,白种人占71%。平均诊断时间(±SD)为11(±9.0)年。超过40%的患者在初次发病时未进行DB检查,从初次发病到确诊DB的平均时间为6.5个月。在DB诊断后和整个观察期间,患者因DB随访的平均(±SD)为3.2(±2.8)次,并继续使用多种标签外处方和非处方治疗来治疗症状。局限性:医疗记录可能不完整或报告不一致,并受到回忆偏差的影响。结论:患者旅程漫长,面临多重挑战,包括DB诊断延迟和反复出现的DB症状,迫切需要采取行动改善DB的诊断和治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Medical Economics
Journal of Medical Economics HEALTH CARE SCIENCES & SERVICES-MEDICINE, GENERAL & INTERNAL
CiteScore
4.50
自引率
4.20%
发文量
122
期刊介绍: Journal of Medical Economics'' mission is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The aim of Journal of Medical Economics is to serve the information needs of the pharmacoeconomics and healthcare research community, to help translate research advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication. Journal of Medical Economics publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信